Literature DB >> 21448170

Markers for the non-invasive diagnosis of mesothelioma: a systematic review.

S van der Bij1, E Schaake, H Koffijberg, J A Burgers, B A J M de Mol, K G M Moons.   

Abstract

BACKGROUND: Numerous markers have been evaluated to facilitate the non-invasive diagnostic work-up of mesothelioma. The purpose of this study was to conduct a structured review of the diagnostic performance of non-invasive marker tests for the detection of mesothelioma in patients with suspected mesothelioma.
METHODS: Studies on the diagnostic accuracy of serum and cytological markers published till 31 December 2009, available in either PUBMED or Embase, to detect or exclude the presence of mesothelioma were extracted. Study quality was assessed with use of the Quadas criteria.
RESULTS: In total, 82 articles were included in this systemic review. Overall, quality of the incorporated studies to address our objective was poor. The most frequently studied immunohistochemical markers for cytological analysis were EMA, Ber-Ep4, CEA, and calretinin. The most frequently investigated serum marker was soluble mesothelin-related protein (SMRP). The markers CEA, Ber-EP4, and calretinin were most valuable in discriminating mesothelioma from other malignant diseases. Markers EMA and SMRP were most valuable in discriminating mesothelioma from non-malignant diseases. No marker performed well in discriminating between mesothelioma and all other diseases.
CONCLUSION: Currently, there is only limited evidence to properly assess the value of non-invasive marker tests in the diagnosis of mesothelioma. Studies were of limited value to address our objective and results showed considerable unexplained study heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448170      PMCID: PMC3078590          DOI: 10.1038/bjc.2011.104

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Empirical evidence of design-related bias in studies of diagnostic tests.

Authors:  J G Lijmer; B W Mol; S Heisterkamp; G J Bonsel; M H Prins; J H van der Meulen; P M Bossuyt
Journal:  JAMA       Date:  1999-09-15       Impact factor: 56.272

Review 2.  Sources of variation and bias in studies of diagnostic accuracy: a systematic review.

Authors:  Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Afina S Glas; Patrick M M Bossuyt; Jos Kleijnen
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

3.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

Review 4.  Characteristics of good diagnostic studies.

Authors:  Ben W Mol; Jeroen G Lijmer; Johannes L H Evers; Patrick M M Bossuyt
Journal:  Semin Reprod Med       Date:  2003-02       Impact factor: 1.303

5.  The efficacy of diagnostic imaging.

Authors:  D G Fryback; J R Thornbury
Journal:  Med Decis Making       Date:  1991 Apr-Jun       Impact factor: 2.583

6.  Interval estimation for the difference between independent proportions: comparison of eleven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

7.  Assessment of diagnostic tests when disease verification is subject to selection bias.

Authors:  C B Begg; R A Greenes
Journal:  Biometrics       Date:  1983-03       Impact factor: 2.571

8.  The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.

Authors:  A A Renshaw; B R Dean; K H Antman; D J Sugarbaker; E S Cibas
Journal:  Chest       Date:  1997-01       Impact factor: 9.410

Review 9.  Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Am J Clin Pathol       Date:  2003-01       Impact factor: 2.493

10.  The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.

Authors:  Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2003-11-10       Impact factor: 4.615

View more
  23 in total

Review 1.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Qianjing Hu; Yongchun Shen; Dan Xu; Tao Wang; Fuqiang Wen
Journal:  Tumour Biol       Date:  2014-03-08

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Capture of mesothelioma cells with 'universal' CTC-chip.

Authors:  Kazue Yoneda; Yasuhiro Chikaishi; Taiji Kuwata; Takashi Ohnaga; Fumihiro Tanaka
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

5.  Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Authors:  Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 6.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

Review 7.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

Review 8.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Authors:  Kevin Hollevoet; Johannes B Reitsma; Jenette Creaney; Bogdan D Grigoriu; Bruce W Robinson; Arnaud Scherpereel; Alfonso Cristaudo; Harvey I Pass; Kristiaan Nackaerts; José A Rodríguez Portal; Joachim Schneider; Thomas Muley; Francesca Di Serio; Paul Baas; Marco Tomasetti; Alex J Rai; Jan P van Meerbeeck
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

9.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

Review 10.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.